Answers are grounded in this paper and cite their sources.
This review provides an overview of recent developments in antiplatelet therapy for cardiovascular disease, highlighting DAPT duration, new regimens, and future targets.
Antiplatelet therapy is a cornerstone in the secondary prophylaxis of adverse cardiovascular events such as myocardial infarction and stroke. The cyclooxygenase inhibitor aspirin remains the most frequently prescribed antiplatelet drug, followed by adenosine diphosphate P2Y 12 receptor blockers. Glycoprotein IIb‐IIIa antagonists are intravenously available antiplatelet agents preventing platelet‐to‐platelet aggregation via the fibrinogen receptor. The thrombin receptor inhibitor vorapaxar allows the targeting of yet a third pathway of platelet activation. Despite the advent of novel agents and major advances in antiplatelet treatment over the last decade, atherothrombotic events still impair the prognosis of many patients with cardiovascular disease. Consequently, antiplatelet therapy remains a field of intense research and a large number of studies on its various aspects are published each year. This review article summarizes recent developments in antiplatelet therapy in cardiovascular disease focusing particularly on the duration of dual antiplatelet therapy, new treatment regimens, the role of platelet function testing, and potential future targets of antiplatelet agents.
No takes yet. Share an insight, caveat, or question.
Gremmel et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: